Eva M. Goetz

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

A. McKenna, K. Cibulskis, S. Gabriel, 2014, Cancer discovery.

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Dennis C. Friedrich, A. McKenna, K. Cibulskis, 2014, Cancer discovery.

Cellular Stress Responses to DNA Damage: An Intracellular Balance between Life, Senescence, and Death

E. Goetz, L. Mayo, M. Jackson, 2011 .

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

A. Letai, L. Garraway, P. Jänne, 2012, Cancer discovery.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

Simion I. Chiosea, Kelsey P. Pendleton, A. McKenna, 2015, JAMA oncology.

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.

L. Garraway, D. Treacy, M. Ghandi, 2014, Cancer research.

Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma.

L. Garraway, E. Goetz, Eva M. Goetz, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.

D. Cacchiarelli, T. Mikkelsen, G. Getz, 2016, Cell reports.

Phenotypic Characterizati on of a Comprehensive Set of MAPK 1 / ERK 2 Missense Mutants Graphical

D. Cacchiarelli, T. Mikkelsen, G. Getz, 2016 .

Signal transduction processes in response to low dose ionizing radiation doses expected during space flight

E. Goetz, D. Boothman, T. Criswell, 2013 .

Secretory Clusterin Is a Marker of Tumor Progression Regulated by IGF-1 and Wnt Signaling Pathways

E. Goetz, D. Boothman, Masatoshi Suzuki, 2009 .